Affymax (AFFY) Closes Stock Offering, Receiving Net Proceeds of $80M
More News related to AFFY
- Affymax to Present at the 12th Annual BIO CEO & Investor Conference
- Affymax (AFFY) Completes Hematide Phase 3
- Affymax Completes Treatment and Last Patient Follow-up in Phase 3 Program for Investigational Drug, Hematide(TM), to Treat Anemia in Chronic Renal Failure
- BioCentury Publishes BioTech Picks for FY10 (HGSI, VRTX, AMGN, More...)
- BioCentury Publishes Investor Picks for New Biotech Bellwethers in 2010
More News related to Equity Offerings
- Ruth’s Hospitality Group (RUTH) Updates on Results from Special Shareholders Meeting
- Hoku Scientific (HOKU) Files 20.01M Common Shelf for a Selling Shareholder
- China Agritech (CAGC) Files $100M Mixed Securities Shelf
- ChinaTel Group (CHTL) Jumps Higher On 'Above-Market' Equity Financing
- Developers Diversified Realty (DDR) Prices 37.3M Common Offering at $8.16/Share
Affymax, Inc. (Nasdaq: AFFY) today announced the closing of its underwritten public offering of 4,726,027 shares of its common stock, which includes the full exercise of the underwriter's overallotment option of 616,438 shares. The net proceeds to the company after deducting underwriting discounts and commissions and estimated offering expenses are approximately $80.0 million.
Cowen and Company, LLC and Lazard Capital Markets LLC were joint book-runners on the offering and RBC Capital Markets Corporation and Robert W. Baird & Co. Incorporated were co-managers for the offering.
Related Categories
Equity OfferingsStocks Mentioned
-0.30Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
